ArticleNPJ precision oncology2026
Integrative immune subtyping of HNSCC reveals clinically relevant phenotypes and treatment-associated transitions.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated histopathology-transcriptomic biomarker enhances survival prediction in HNSCC patients treated with immunotherapy.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) shows marked heterogeneity in clinical behavior, treatment response, and immune contexture. Existing molecular and immune classification systems are often derived from small, homogeneous cohorts and lack integration of multimodal data, limiting clinical relevance. We performed an integrated multi-omics analysis of transcriptomic and genomic data (copy number alterations and single-nucleotide variants) from 1149 tumors across 1102 HNSCC patients spanning multiple treatment settings. Using Similarity Network Fusion (SNF) on immune-related gene profiles, we identified immune subtype clusters (ISCs) and characterized them through mutational, transcriptional, immune cell enrichment, hypoxia, and established molecular subtype analyses. Clinical associations, including progression-free survival, were evaluated in first-line and post-metastatic settings. Four ISCs were defined: ISC1, immune-cold and EMT-enriched; ISC2, immune-activated; ISC3, mixed immune-regulatory with stromal enrichment; and ISC4, immunosuppressed. These subtypes showed distinct clinical outcomes and differential responses to checkpoint inhibitors, chemotherapy, and combination therapies. Analysis of 44 patients with matched pre- and post-treatment tumors revealed dynamic immune-state transitions, with checkpoint inhibition promoting immune activation and chemotherapy enriching immunosuppressive signaling. This study establishes a clinically relevant immune subtyping framework for HNSCC that captures dynamic tumor-immune states linked to treatment response and survival, supporting its utility in guiding immune-based therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.